Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rimeporide (EMD-87580) 是有效的 Na+/H+交换泵 (NHE-1) 选择性抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 631 | 现货 | ||
2 mg | ¥ 918 | 现货 | ||
5 mg | ¥ 1,490 | 现货 | ||
10 mg | ¥ 2,530 | 现货 | ||
25 mg | ¥ 4,320 | 现货 | ||
50 mg | ¥ 6,160 | 现货 | ||
100 mg | ¥ 8,480 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,630 | 现货 |
产品描述 | Rimeporide (EMD-87580) (EMD-87580) is a potent and selective Sodium hydrogen exchange 1 (NHE-1) inhibitor. |
体外活性 | Treatment for 24 h with 10 μM phenylephrine significantly increased cell surface area to 129.6 3.1% of control values. The hypertrophic effect of phenylephrine was completely abrogated by 5 μM of EMD87580 [1]. |
细胞实验 | To induce hypertrophy, myocytes were treated for 10 min or 24 h as appropriate and noted under Results with 10 μM phenylephrine in the absence or presence of the following agents: the NHE-1 inhibitor EMD87580 (5 μM) or cariporide (5 μM), the JNK1/2 inhibitor SP600125, the p38 inhibitor SB203580, the ERK1/2 inhibitor PD98059 (all at 10 μM), and the reverse mode Na+-Ca2+ exchange inhibitor KB-R7943 or SN-6 (both at 10 μM). All drugs were added 30 min before the addition of phenylephrine [1]. |
动物实验 | Two groups were studied. The treatment group (n = 5) received EMD 87580 at a dose of 5 mg/kg IV bolus 5 min before aortic cross-clamping and 10 mol/L EMD 87580 in the cardioplegic solution. The control group (n = 9) received the same volume of saline vehicle. Systemic pretreatment was used to ensure drug availability during the ischemic period prior to CPA. Direct infusion via cardioplegia ensures drug delivery at the time of ischemia (CPA), and it decreases the variability of drug delivery that may occur during the hemodilution with CPB initiation. Incorporation into the cardioplegia also minimizes the potential variable of drug/extracorporeal circuit interactions. Using this dosing regimen, the plasma concentration of EMD 87580 was in the 2,500 to 3,000 ng/mL range at 10 min after CPB. This concentration has been shown to be effective at Na+/H+ exchanger inhibition in vitro [2]. |
别名 | EMD-87580 |
分子量 | 333.38 |
分子式 | C11H15N3O5S2 |
CAS No. | 187870-78-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 15 mg/mL (50 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.9996 mL | 14.9979 mL | 29.9958 mL | 74.9895 mL |
5 mM | 0.5999 mL | 2.9996 mL | 5.9992 mL | 14.9979 mL | |
10 mM | 0.3 mL | 1.4998 mL | 2.9996 mL | 7.499 mL | |
20 mM | 0.15 mL | 0.7499 mL | 1.4998 mL | 3.7495 mL | |
50 mM | 0.06 mL | 0.3 mL | 0.5999 mL | 1.4998 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Rimeporide 187870-78-6 Membrane transporter/Ion channel Sodium Channel Inhibitor EMD87580 Sodium-hydrogen Exchanger EMD 87580 Sodium/hydrogen Exchanger inhibit Na+/H+ Exchanger (NHE) EMD-87580 inhibitor